Elite Pharmaceuticals Reports GAAP EPS of $0.03 and Revenue Growth
Elite Pharmaceuticals reported FY GAAP earnings per share (EPS) of $0.03 with revenue reaching $148.87 million, representing a year-over-year increase of 77.1%. The results highlight strong performance in the company's financial metrics.
Topics: Earnings Revenue Growth